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INTRODUCTION
The premenstrual syndromes are char-
acterised by physical and/or affective 
symptoms that occur in the luteal phase 
of the menstrual cycle.  Symptoms and 
severity of symptoms vary and therefore 
the impact of these syndromes on psy-
chosocial and economical aspects is 
difficult to quantify and generalise.
CLINICAL MANIFESTATIONS
Premenstrual syndrome (PMS) will af-
fect about 25% of women with a regular 
menstrual cycle, depending on the 
strictness of criteria.  Physical and be-
havioural symptoms can occur.
Premenstrual dysphoric disorder 
(PMDD) is a more severe type of 
PMS where the psychological and 
behavioural symptoms of labile and 
depressed mood, anger, irritability and 
internal tension are prominent.  PMDD 
occurs in about 5% of women with regu-
lar cycles.1  
While over 150 symptoms have been 
ascribed to PMS, the most common 
symptoms are listed in tables 1 and 2. 
To accurately diagnose these disorders, 
recognized criteria should be used as 
many women suffer from other underly-
ing disorders exacerbated pre-menstru-
ally and should not be treated as PMS.2
DIAGNOSTIC CRITERIA
The criteria of the American College 
of Obstetricians and Gynecologists for 
PMS are widely used (table 2).  These 
criteria describe affective and somatic 
symptoms in a cyclical fashion with a 
severity criterion of identifiable social or 
economic dysfunction.3 
For the diagnosis of PMDD the most 
widely used criteria is that of the DSM-IV 
(table 3).
Only affective symptoms are required 
with prospective confirmation, correct 
timing and a severity clause.4
PATHOGENESIS
Ovarian steroid hormone fluctuations 
are clearly needed to precipitate the 
symptoms.  On the other hand it is also 
clear that these cyclical changes are not 
solely responsible for either the mood 
changes or the systemic manifestations 
of the syndrome and disorder.  Suscep-
tible symptomatic women have levels 
comparable to levels found in asymp-
tomatic women.5
Interaction between the ovarian ste-
roid hormones and neurotransmitters 
seems to play a major role, with sero-
tonin currently most implicated.  While 
susceptibility to both mood disorders 
Table 2: The diagnostic criteria of the American College of Obstetricians and Gynecologists 
for premenstrual syndrome.
Table 1: Common symptoms of premenstrual 
syndrome.






Also: acne, dizziness, palpitations,
         gastro-intestinal upset






Also: anger, increased appetite, easy 
crying, forgetfulness
DIAGNOSTIC CRITERIA FOR PREMENSTRUAL SYNDROME
* At least one of the following affective and somatic symptoms must be reported during 
  the five days before menses in each of the three prior menstrual cycles:
    Affective Symptoms
    - Depression
    - Angry outbursts
    - Irritability
    - Anxiety
    - Confusion
    - Social Withdrawal
    Somatic Symptoms
    - Breast tenderness
    - Abdominal bloating
    - Headache
    - Swelling of extremities
* These symptoms are relieved within 4 days of the onset of menses without recurrence           
   until at least cycle day 13.
*  The symptoms are present in the absence of any pharmacologic therapy, hormone 
    ingestion, or drug or alcohol use.
*  The symptoms occur reproducibly during two cycles of prospective recording.
*  The patient suffers from identifiable dysfunction in social or economic performance.
This article discusses the differences between premenstrual syndrome and premenstrual dysphoric disorder and outlines a 
treatment approach.
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and PMS and PMDD are strongly in-
herited, predisposition to other mood 
disorders do not seem to predict PMS/
PMDD.6
Steroid hormone fluctuations indeed 
cause cyclical change in the opoid 
system (beta-endorphin), the GABA 
system and the serotonin system cen-
trally.7,8 It appears that the fluctuations 
caused in these neurotransmitters are 
accentuated in women suffering symp-
toms of PMS/PMDD, pointing towards 
increased biological sensitivity to cycli-
cal change.9,10
This genetically determined bio-
logical vulnerability is most likely also 
affected by personal and social factors 
influencing the severity of symptoms. 
Several recent studies, however, have 
challenged the importance of external 
factors like psychosocial stress.11,12
TREATMENT 
Premenstrual symptoms are common 
and do not need treatment, the premen-
strual syndrome (PMS), however is less 
common and more frequently would 
need intervention.  The premenstrual 
dysphoric disorder (PMDD) is much 
less common and would mostly need 
treatment.  Because these disorders 
are not easy to diagnose, the symptoms 
frequently not easy to quantify, the 
response to treatment is also not easy 
to measure.  Patients would commonly 
perceive their symptoms as varying 
substantially from month to month and 
this makes the response to treatment 
even more difficult to judge.
It would be important to explain to 
patients who present with this syndrome 
complex that the problem is not caused 
by an abnormality in hormone secretion. 
It is also important to point out that this 
problem is not as easily treatable as 
pneumonia where one can use a course 
of antibiotics that solves the disease 
permanently.  The treatment plan would 
virtually always be a long-term plan.
Different treatment options will be 
discussed with the evidence for pre-
scribing these therapies.
Serotonin Reuptake Inhibitors
This group of drugs probably have the 
best evidence for being effective in this 
syndrome.  The efficacy of particularly 
fluoxetine has been documented in quite 
a number of studies.  The typical positive 
response rate is as high as 75%, with the 
usual prescribed dosage 20mg per day. 
A higher dose is not more effective and 
significantly increases the side effects. 
It is also important to note from these 
trials that both the affective and somatic 
symptoms improve on this drug and 
that the response is maintained over the 
long term.13, 14  Fluoxetine is approved 
by the FDA for PMDD but not by the Eu-
ropean drug regulators because of their 
concern with lack of strict diagnostic 
criteria in certain trials and their concern 
with possible inappropriate prescribing 
practices.  There are also publications 
to support the use of other SRI’s such as 
paroxetine and citalopram.
Only administering the drugs during 
the luteal phase is also supported by 
placebo controlled trials and might well 
be the better option to reduce side-ef-
fects and cost.  The drug would typically 
be given from about day 14 to the first 
day of menstruation.15   Physical symp-
toms might not respond as well on the 
intermittent regime as continuous use.
Antidepressants not belonging to the 
group of SRI’s such as MAOI’s and the 
tricyclic antidepressants are unfortu-
nately not effective in this condition.  The 
same is true for lithium.  These drugs do 
not fare better than placebo in trials and 
should not be used.
Benzodiazepines
Alprazolam may be beneficial in women 
with PMS but does not seem to work 
well in patients that suffer from PMDD. 
It would not be the first drug to use and 
the addictive potential is real.16,17,18
Oral Contraceptives
Inducing anovulation should alleviate 
the symptoms of this disease but sev-
eral studies failed to show any improve-
ment using some of the older formula-
tions.  There are however more than one 
placebo controlled trial where the newer 
progestogen drosperinone was used. 
In both the contraceptive formulations 
that contain drosperinone (with 24 
and 21 day active tablets) statistically 
significant beneficial effects have been 
shown.19,20
GnRH analogues
By inducing anovulation with these 
agents a woman is relieved from all 
hormonal fluctuations and PMS/PMDD 
will improve.  It is more effective in 
preventing physical and irritability 
symptoms than depressive symptoms. 
Unfortunately side effects such as 
flushing and emotional sequelae are 
common.  Add-back therapy to control 
the hypo-estrogenic symptoms will give 
protection against the flushing and bone 
RESEARCH CRITERIA FOR PREMENSTRUAL DYSPHORIC DISORDER
A)  In most menstrual cycles during the past five year, five (or more) of the 
      following symptoms were present for most of the time during the last week 
      of the luteal phase, began to remit within a few days after the onset of the
      follicular phase, and were absent in the week post menses, with at least one
      of the symptoms being either of the first four:
      1.  Markedly depressed mood, feelings of hopelessness, or self-deprecating
           thoughts
      2.  Marked anxiety, tension, feelings of being “keyed up” of “on edge”
      3.  Marked affective liability (e.g., feeling suddenly sad or tearful or increased
           sensitivity to rejection)
      4.  Persistent and marked anger or irritability or increased interpersonal conflicts
      5.  Decreased interest in usual activities (e.g., work, school friends, hobbies)
      6.  Subjective sense of difficulty in concentrating
      7.  Lethargy, easy fatigability, or marked lack of energy
      8.  Marked change in appetite, overeating, or specific food cravings
      9.  Hypersomnia or insomnia
    10.  A subjective sense of being overwhelmed or out of control
    11.  Other physical symptoms, such as breast tenderness or swelling, headaches,
           joint or muscle pain, a sensation of “bloating”, weight gain
B)  The disturbance markedly interferes with work or school or with usual social
       activities and relationships with others (e.g., avoidance of social activities,
       decreased productivity and efficiency at work or school).
C)  The disturbance is not merely an exacerbation of the symptoms of another disorder, 
       such as Major Depressive Disorder, Panic Disorder, Dysthymic Disorder, or a
       Personality Disorder (although it may be superimposed on any of these disorders).
D)  Criteria A, B, and C must be confirmed by prospective daily ratings during at least
       two consecutive symptomatic cycles. (The diagnosis may be made provisionally 
       prior to this confirmation.)
Table 3:  The DSM IV diagnostic criteria of the Amercian Psychiatric Association.  (Diagnostic 
and Statistical Manual Edition IV) 
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loss but still does not make this a viable 
option in the long term.  It could however 
be used to predict the effect of surgical 
oophorectomy.21,22,23
Danazol
Danazol does improve the symptoms 
but only once high enough dosages 
are used to suppress ovulation.  Unfor-
tunately the androgenic side effects are 
too severe at these dosages for most 
patients.
Spironolactone
This steroid like diuretic should have the 
best likelihood to be effective but results 
of trials are at best ambiguous.
 
Exercise
It is difficult to investigate this option in a 
blinded manner but trials and observa-
tional data suggest a beneficial effect. 
Exercise should be recommended.
Calcium
There are studies that show a beneficial 
response on calcium supplementation if 
600mg twice daily is used.  Other stud-
ies show a dose related association 
between intake and severity of symp-
toms.24
Other Supplements
The response on vitamin B6 is at best not 
dramatic but it might well be worth try-
ing.25   Magnesium supplementation has 
even less convincing scientific evidence 
but small trials have described modest 
improvements.  Vitamin E supplementa-
tion at 400IU per day was described in 
small studies to improve the physical 
and affective symptoms.
Evening Primrose oil, gingko biloba 
and essential free fatty acids really have 
no evidence to show their efficacy and 
progesterone has been shown not to 
work.
SUGGESTED APPROACH TO MAN-
AGEMENT:
In patients where the diagnosis has 
been established and the woman is 
symptom free in the follicular phase, 
it would be important to quantify her 
symptoms.  If the situation is manage-
able the patient should be advised to 
exercise in a scheduled program with 
significant intensity.  Vitamin B6 should 
probably be offered as it might work and 
is harmless as long as doses not more 
than 100mg per day is used.
If distress is judged to be severe 
SRI’s should be offered.  About 30% 
of patients will not respond to SRI’s and 
it might be worth while increasing the 
dose, changing to a 2nd SRI or switching 
from luteal phase therapy to continuous 
therapy.  A few patients will have signifi-
cant side effects such as nausea, head-
ache, poor libido and anorgasmia.
Drosperinone containing contracep-
tives should frequently be used and in 
recalcitrant cases alprazolam, spirono-
lactone and calcium supplements might 
offer some relief.  As an absolute last 
resort and when GnRH has been suc-
cessful in alleviating symptoms removal 
of the uterus and ovaries should be con-
templated.   
See CPD Questionnaire, page 39
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